{"id":2095,"date":"2020-07-28T10:19:55","date_gmt":"2020-07-27T21:19:55","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=2095"},"modified":"2020-07-28T10:19:55","modified_gmt":"2020-07-27T21:19:55","slug":"genetic-prognostic-factors-in-cll-treated-with-novel-compounds","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=2095","title":{"rendered":"Genetic Prognostic Factors in CLL Treated With Novel Compounds"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column width=&#8221;1\/1&#8243;][vc_custom_heading heading_semantic=&#8221;h1&#8243; text_size=&#8221;h1&#8243;]Genetic Prognostic Factors in CLL Treated With Novel Compounds[\/vc_custom_heading][vc_column_text]<a href=\"https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/chronic-lymphocytic-leukemia\/chronic-leukemia-cll-genetic-prognostic-factors-novel-compounds\/\">This article was originally published by Cancer Therapy Advisor<\/a><\/p>\n<div class=\"article__content--footer\">\n<div class=\"row\">\n<div class=\"col\">\n<div class=\"chips row\" data-module-track-action=\"Chip in article_Click_Healio News Article\" data-module-track-label=\"Chip in article_Healio News Article\">\n<div class=\"chip\" data-item=\"{6a060023-b14d-469e-966c-0c57c7205833}\">\n<div class=\"detail\">\n<div class=\"detailBody\">\n<p>Treatment with obinutuzumab plus venetoclax (VenG) was associated with improved outcomes compared with obinutuzumab plus chlorambucil (CGlb) among patients with chronic lymphocytic leukemia (CLL) and established unfavorable genetic factors, according to a study published in\u00a0<em>Blood<\/em>.<sup>1<\/sup><\/p>\n<p>\u201cGenetic parameters are established prognostic factors in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy, but are less well studied with novel compounds,\u201d the authors wrote.<\/p>\n<p>Unmutated\u00a0<em>IGHV<\/em>, mutated\u00a0<em>TP53<\/em>, and deletion of chromosome 17p (del[17p]) that contains the\u00a0<em>TP53<\/em>\u00a0locus, are associated with progression and shorter survival among patients with CLL treated with chemoimmunotherapy. Other genetic markers have been identified that are also prognostic for outcomes.<\/p>\n<p>This analysis used data from the multicenter, phase 3 CLL14 trial, which randomly assigned 432 patients with\u00a0<a href=\"https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/chronic-lymphocytic-leukemia\/\" data-feathr-click-track=\"true\">CLL<\/a>\u00a0to receive first-line VenG or CGlb. The analysis used fluorescence in situ hybridization (FISH), DNA sequencing, and next-generation sequencing to evaluate genetic prognostic factors.<\/p>\n<div class=\"reco-in-article\">\n<div class=\"reco-in-article-title\">Today\u2019s Top Picks for You on Cancer Therapy Advisor<\/div>\n<div id=\"bibblio_recommended_box\">\n<div class=\"bib__module bib--row-3 bib--txt-3\"><a class=\"bib__link bib__link--1 \" href=\"https:\/\/www.cancertherapyadvisor.com\/uncategorized\/chronic-leukemia-cll-chemotherapy-regimen-consist-3-novel-agents\/\" target=\"_self\" data-feathr-click-track=\"true\" rel=\"noopener noreferrer\"><span class=\"bib__info\"><span class=\"bib__title\"><span class=\"bib__name\">Chemotherapy-Free Regimen Consisting of 3 Novel Agents for Previously Untreated, Poor Prognosis CLL<\/span><\/span><\/span><\/a><a class=\"bib__link bib__link--2 \" href=\"https:\/\/www.cancertherapyadvisor.com\/uncategorized\/tp53-ovarian-cancer-wee1-kinase-inhibitor-pfs-survival\/\" target=\"_self\" data-feathr-click-track=\"true\" rel=\"noopener noreferrer\"><span class=\"bib__info\"><span class=\"bib__title\"><span class=\"bib__name\">WEE1 Kinase Inhibitor Improved PFS in\u00a0<i>TP53<\/i>-Mutated Ovarian Cancer<\/span><\/span><\/span><\/a><a class=\"bib__link bib__link--3 bib__link--image\" href=\"https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/chronic-lymphocytic-leukemia\/prognostic-and-clinical-significance-of-genes-in-chronic-lymphocytic-leukemia\/\" target=\"_self\" data-feathr-click-track=\"true\" rel=\"noopener noreferrer\"><span class=\"bib__info\"><span class=\"bib__title\"><span class=\"bib__name\">Resequencing Gene Panels May Improve Prognostic Measurements for Chronic Lymphocytic Leukemia<\/span><\/span><\/span><\/a><\/div>\n<div><\/div>\n<\/div>\n<\/div>\n<div><\/div>\n<div><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/chronic-lymphocytic-leukemia\/chronic-leukemia-cll-genetic-prognostic-factors-novel-compounds\/\">To continue reading click here\u00a0<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.<\/p>\n","protected":false},"author":1,"featured_media":2096,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-2095","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/07\/CLL-purple.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/2095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2095"}],"version-history":[{"count":2,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/2095\/revisions"}],"predecessor-version":[{"id":2098,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/2095\/revisions\/2098"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/2096"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}